Providing Process Development, Flexible Manufacturing, and Analytical Services to the Global Biotech Community
Cook Pharmica LLC is a biopharmaceutical contract manufacturer of mammalian cell-culture products. Cook Pharmica's mission is to provide process development, flexible manufacturing, and analytical services to the global biotech community, enabling its partners to bring their life-saving discoveries to patients. Founded in 2004, Cook Pharmica is a privately held, wholly-owned subsidiary of Cook Incorporated.
Cook Pharmica LLC is a biopharmaceutical contract manufacturer of mammalian cell-culture products. Cook Pharmica's mission is to provide process development, flexible manufacturing, and analytical services to the global biotech community, enabling its partners to bring their life-saving discoveries to patients. Founded in 2004, Cook Pharmica is a privately held, wholly-owned subsidiary of Cook Incorporated.
The current cGMP manufacturing facility was designed to support clinical and small-scale commercial products. Within the manufacturing area are two (2) 2,500L, one (1) 600L stainless steel bioreactors, and disposable bioreactors ranging in size up to 100L. The facility's design incorporates disposable technologies, segregated production rooms, innovative wall pass-throughs and uni-directional flow of operators, and equipment and supplies to reduce the risk of contamination.
Cook Pharmica's development group offers a variety of mammalian and microbial development services, such as: cell line or strain development, clone selection, cell line adaptation, media optimization, process development, purification development, analytical development, and pre-clinical manufacturing.
Additional contract services offered are analytical and microbial testing, CGMP cell banking, stability storage and testing, and regulatory assistance with submissions.
Centrally located in Bloomington, Indiana, Cook Pharmica offers a new level of transparency by giving clients the opportunity to monitor projects when away from the facility through secure Internet webcams positioned to give full visibility at each stage of production. Cook Pharmica is committed to maintaining strict compliance to regulatory agency guidelines and cGMP procedures, as well as providing the highest levels of quality assurance and quality control in all functions of our facility.
With a current facility of 124,000 square feet that is expandable to 450,000 square feet, and a second independent building with an additional 450,000 square feet, Cook Pharmica is well positioned and committed to expand production capacity and capabilities to meet the needs of customers.
Contact Information:
Cook Pharmica LLC
1300 S. Patterson Drive
P.O. Box 970
Bloomington, IN 47402-0970
Tel: 877.312.2665 (domestic)
812.355.6746 (international)
Fax: 812.336.7167
Email: busdev@cookpharmica.com
Website: www.cookpharmica.com
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
